New Class of Drug Therapies with Low Toxicity Treating HER2-Positive Breast Cancer
Read Transcript
Download Transcript 
Share This Video
Take Our SurveyWomen with HER2 positive breast cancer used to have a poorer prognosis. While it is still a serious breast cancer subtype, the latest news from ASCO shows yet another promising drug to knock the cancer back and Dr. Julie Gralow, director of medical oncology at the University of Washington and the Seattle Cancer Alliance says it is big news. In this video, Dr. Gralow also comments on research for women with the “triple negative” subtype and also about preventing the bone complications of advanced breast cancer.
Health Topics: Breast Cancer, Metastatic Breast Cancer
Get Email Updates:
Get updated automatically when new content about Metastatic Breast Cancer has been posted.
Privacy Policy
Privacy Policy
Metastatic Breast CancerMore Health Topics
Experts & Guests
|
Julie Gralow, M.D.
Director of Breast Medical Oncology, Seattle Cancer Care Alliance
Dr. Julie Gralow is Director of Breast Medical Oncology at Seattle Cancer Care Alliance and is an associate professor in the oncology division at University of Washington School of Medicine. She received her medical degree from the University of Southern California in Los Angeles. Dr. Gralow’s specialty and research focus is breast cancer.
more >
|
|
|
